Hemostemix Inc. announces the 20th clinical trial site is active and the 56th trial subject was enrolled as of December 31, 2019. The Hemostemix Phase II study of ACP-01 is an international 20 center randomized double-blind placebo- controlled clinical trial to assess the safety and efficacy of ACP-01 injected into the lower extremity of 95 CLI patients who have exhausted all other options. A futility analysis for potentially stopping enrolment into the study will be performed when 42 subjects have completed at least 26 weeks of follow-up.: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted ".healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years." Patients with critical limb ischemia (CLI) face a high risk of amputation once revascularization surgery options are exhausted. It is estimated that 160,000 amputations are carried out annually in the USA due to the failure of revascularization.